Published in Gastroenterol Res Pract on November 15, 2009
Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation. Virchows Arch (2014) 0.84
Transjugular liver biopsy. Semin Intervent Radiol (2012) 0.83
Gray scale and contrast-enhanced ultrasound imaging of malignant liver tumors of vascular origin. United European Gastroenterol J (2015) 0.79
Prediction of outcome and selection of the liver transplantat candidate in acute liver failure. Front Physiol (2012) 0.77
Evaluation of the Success Rate of Ultrasound-guided Transjugular Liver Biopsy (TJLB) and the Associated Complications. Electron Physician (2016) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Liver biopsy. N Engl J Med (2001) 9.91
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17
Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol (2003) 3.62
Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. J Hepatol (2007) 2.52
Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut (2006) 1.61
CATHETER BIOPSY. EXPERIMENTAL TECHNIC FOR TRANSVENOUS LIVER BIOPSY. Radiology (1964) 1.26
Transjugular liver biopsy: a retrospective analysis of 601 cases. J Vasc Interv Radiol (2008) 1.25
Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol (2003) 1.04
Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol (1983) 1.02
Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther (2004) 1.01
Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol (2007) 1.00
Contribution of transjugular liver biopsy in patients with the clinical presentation of acute liver failure. Cardiovasc Intervent Radiol (2006) 0.98
Various approaches to obtaining liver tissue--choosing the biopsy technique. J Hepatol (1996) 0.92
Approaches to liver biopsy techniques--revisited. Semin Liver Dis (2006) 0.91
The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology (1993) 0.91
Transjugular liver biopsy using ultrasonographic guidance for jugular vein puncture and an automated device for hepatic tissue sampling: a retrospective analysis of 200 consecutive cases. Abdom Imaging (2008) 0.89
A comparison of four- versus three-pass transjugular biopsy using a 19-G Tru-Cut needle and a randomized study using a cassette to prevent biopsy fragmentation. Cardiovasc Intervent Radiol (2008) 0.88
Transjugular liver biopsy: a comparison of aspiration and trucut techniques. Liver (1997) 0.85
The value of early transjugular liver biopsy after liver transplantation. Transplantation (1996) 0.84
Transjugular liver biopsy in patients with diffuse liver disease: comparison of three cores with one or two cores for accurate histological interpretation. Liver Int (2007) 0.81
Transjugular liver biopsy in patients with living donor liver transplantation: comparison with percutaneous biopsy. Liver Transpl (2008) 0.78
[Transjugular liver biopsy: trucut or aspiration biopsy with modified Ross needles?]. Rofo (2003) 0.78
Transjugular liver biopsy and cholangiography. Fortschr Geb Rontgenstr Nuklearmed (1973) 0.77
[Biopsy diagnosis of chronic hepatitis]. Z Gastroenterol (2004) 0.77
Transjugular liver biopsy: histological diagnosis success comparing the trucut to the modified aspiration Ross needle. Arq Gastroenterol (2004) 0.77
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol (2012) 5.86
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut (2013) 4.07
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med (2012) 2.86
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology (2008) 2.56
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Portopulmonary hypertension and hepatopulmonary syndrome. Lancet (2004) 2.48
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 2.43
Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology (2004) 2.41
Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34
Hepatitis delta virus. Lancet (2011) 2.32
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med (2009) 2.26
MicroRNAs play a role in spontaneous recovery from acute liver failure. Hepatology (2014) 2.23
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology (2013) 2.12
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell (2008) 2.12
Microbiologic analysis of peri-pancreatic fluid collected during EUS in patients with pancreatitis: impact on antibiotic therapy. Gastrointest Endosc (2013) 2.10
Endoscopic vacuum-assisted closure of upper intestinal anastomotic leaks. Gastrointest Endosc (2008) 2.06
Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl (2006) 2.04
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6 to control centrosome duplication. Nat Cell Biol (2011) 1.99
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology (2007) 1.97
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Involvement of TRAIL and its receptors in viral hepatitis. FASEB J (2002) 1.97
Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology (2012) 1.94
The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol (2008) 1.92
Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature (2004) 1.91
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Management of major postsurgical gastroesophageal intrathoracic leaks with an endoscopic vacuum-assisted closure system. Gastrointest Endosc (2009) 1.89
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev (2004) 1.88
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol (2011) 1.86
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell (2013) 1.86
Hepatic gas gangrene following liver transplantation. Liver Transpl (2007) 1.85
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol (2010) 1.80
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int (2009) 1.78
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol (2004) 1.76
Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment. Gut (2011) 1.75
Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology (2010) 1.75
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation (2009) 1.73
Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes (2004) 1.73
Aftercare for patients with transplanted organs. Dtsch Arztebl Int (2009) 1.72
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70
Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology (2010) 1.70
Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury. Am J Pathol (2003) 1.69